Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma

American Journal of Clinical Pathology

Volumn 138, Issue 3, 2012, Pages 390-396

  Cenci, Tonia ^a   Martini, Maurizio ^a   Montano, Nicola ^a   D'Alessandris, Quintino G ^a   Falchetti, Maria Laura ^b   Annibali, Daniela ^b   Savino, Mauro ^b   Bianchi, Federico ^a   Pierconti, Francesco ^a   Nasi, Sergio ^b   Pallini, Roberto ^a   Larocca, Luigi Maria ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CNR   (Italy)

Author keywords

BMI1; c Myc; Glioblastoma multiforme

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; APOPTOSIS; ARTICLE; BMI1 GENE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOBLASTOMA; H3K9AC GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE; ONCOGENE C MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84865409285     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPRXHNJQLO09QA     Document Type: Article

References (37)

1. Stupp R, Mason WP, van den Bent MJ, et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. National Cancer Institute of Canada Clinical Trials Group. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19:1-11. (Pubitemid 29018404)
3. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8:976-990
4. Cole MD, Cowling VH. Transcription-independent functions of MYC: regulation of translation and DNA replication. Nat Rev Mol Cell Biol. 2008;9:810-815.
5. Martinato F, Cesaroni M, Amati B, et al.Analysis of Myc-induced histone modifications on target chromatin. PLoS One. 2008;3:e3650.
6. Thorne JL, Campbell MJ, Turner BM. Transcription factors, chromatin and cancer. Int J Biochem Cell Biol. 2009;41:164-175.
7. Faria C, Miguéns J, Antunes JL, et al.Pediatric brain tumors: genetics and clinical outcome. J Neurosurg Pediatr. 2010;5:263-270.
8. Scheurlen WG, Schwabe GC, Joos S, et al.Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol. 1998;16:2478-2485.
9. Zitterbart K, Filkova H, Tomasikova L, et al.Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma. J Neurooncol. 2011;102:25-33.
10. Herms JW, von Loewenich FD, Behnke J, et al.c-myc oncogene family expression in glioblastoma and survival. Surg Neurol. 1999;51:536-542. (Pubitemid 29218069)
11. Zheng H, Ying H, Yan H, et al.p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008;455:1129-1133.
12. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell. 2004;118:409-418. (Pubitemid 39485661)
13. Jacobs JJ, Scheijen B, Voncken JW, et al.Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 1999;13:2678-2690. (Pubitemid 29508555)
14. Vonlanthen S, Heighway J, Altermatt HJ, et al.The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4AARF locus expression. Br J Cancer. 2001;84:1372-1376. (Pubitemid 32522106)
15. Beà S, Tort F, Pinyol M, et al.BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001;61:2409-2412. (Pubitemid 32685815)
16. Leung C, Lingbeek M, Shakhova O, et al.Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature. 2004;428:337-341. (Pubitemid 38418806)
17. Zakrzewska M, Zakrzewski K, Grešner SM, et al.Polycomb genes expression as a predictor of poor clinical outcome in children with medulloblastoma. Childs Nerv Syst. 2011;27:79-86.
18. Shakhova O, Leung C, Marino S. Bmi1 in development and tumorigenesis of the central nervous system. J Mol Med. 2005;83:596-600. (Pubitemid 41176068)
19. Guney I, Wu S, Sedivy JM. Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). Proc Natl Acad Sci U S A. 2006;103:3645-3650. (Pubitemid 43376609)
20. Guo WJ, Datta S, Band V, et al.Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell. 2007;18:536-546. (Pubitemid 46213222)
21. Korur S, Huber RM, Sivasankaran B, et al.GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS One. 2009;4:e7443.
22. Kleihues P, Louis DN, Scheithauer BW, et al.The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215-225. (Pubitemid 34212595)
23. Martini M, Pallini R, Luongo G, et al.Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer. 2008;123:2955-2960.
24. Pallini R, Ricci-Vitiani L, Banna GL, et al.Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 2008;14:8205-8212.
25. de Haas T, Hasselt N, Troost D, et al.Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB and CCNB1 expression. Clin Cancer Res. 2008;14:4154-4160.
26. Hayry V, Tynninent O, Haapasalo HK, et al.Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumors. Neuropathol Appl Neurobiol. 2008;34:555-563.
27. Faria MH, Gonçalves BP, do Patrocínio RM, et al.Expression of Ki-67, topoisomerase II alpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology. 2006;26:519-527. (Pubitemid 44800287)
28. Orian JM, Vasilopoulos K, Yoshida S, et al.Overexpression of multiple oncogenes related to histological grade of astrocytic glioma. Br J Cancer. 1992;66:106-112.
29. Sasaki N, Kuroda J, Nagoshi H, et al.Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. Exp Hematol. 2011;39:817-828.e1.
30. Wu X, Cai ZD, Lou LM, et al.Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients [published online ahead of print September 2, 2011]. Cancer Epidemiol. 2012;36:212-216.
31. Yasojima H, Shimomura A, Naoi Y, et al.Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Eur J Cancer. 2011;47:1779-1788.
32. Abdouh M, Facchino S, Chatoo W, et al.BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci. 2009;29:8884-8896.
33. von Bueren AO, Oehler C, Shalaby T, et al.c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients. BMC Cancer. 2011;11:74.
34. Järvinen K, Hotti A, Santos L, et al.Caspase-8, c-FLIP, and caspase-9 in c-Myc-induced apoptosis of fibroblasts. Exp Cell Res. 2011;317:2602-2615.
35. De Salvo M, Maresca G, D'agnano I, et al.Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells. Int J Radiat Biol. 2011;87:518-533.
36. Soucek L, Jucker R, Panacchia L, et al.Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res. 2002;62:3507-3510. (Pubitemid 34651400)
37. Savino M, Annibali D, Carucci N, et al.The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One. 2011;6:e22284.